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IBMTR/ABMTR Mortimer M. Bortin Awards 
for Outstanding Research in Bone Marrow Transplantation
Mortimer M. Bortin, M.D., was one of the founding members of the IBMTR and served as its Scientific
Director for more than 30 years. The Mortimer M. Bortin Award, established to commemorate Dr. Bortin’s con-
tribution to the field of transplantation, is presented each year to one or more investigators submitting abstracts
for presentation at the annual IBMTR/ABMTR meeting.  The abstracts must address important issues in experi-
mental or clinical blood and marrow transplantation and be deemed to be of outstanding scientific merit.
This year, three $1,000 awards will be presented on behalf of the Mortimer M. Bortin Fund Awards Committee.
The awards are supported by an educational grant from Gambro BCT, Inc.
NO DELETERIOUS EFFECT OF HLA-MISMATCHING OUTSIDE CROSS
REACTIVE GROUPS (CREG) COMPARED TO WITHIN CREG MISMATCHES
FOLLOWING UNRELATED DONOR BONE MARROW TRANSPLANT
Wade, J.A.2; Takemoto, S.K.3; Thompson, J.4; Hurley, C.K.5; Fuller,
T.C.6; Rodey, G.7; Davies, S.M.8; Confer, D.L.1; Kollman, C.1 1.
National Marrow Donor Program, Minneapolis, MN; 2. University of
Toronto, Toronto, ON, Canada; 3. UCLA Dept. of Pathology, Los
Angeles, CA; 4. University of Kentucky, Lexington, KY; 5. Georgetown
University, Washington, DC; 6. University of Utah, Salt Lake City,
UT; 7. Baylor College of Medicine, Houston, TX; 8. University of Min-
nesota, Minneapolis, MN
Strategies for selecting a partially HLA-mismatched donor vary
when a full match cannot be identiﬁed. Some transplant centers
have limited donor selection to mismatches within an HLA-A or
HLA-B CREG. HLA antigens within a CREG share polymorphic
sequences which form public epitopes identiﬁed by alloantisera.
To assess whether an HLA mismatch within a CREG group
(“minor”) may result in better outcome than a mismatch outside
CREG groups (“major”), we analyzed validated outcomes data
from 6931 transplants facilitated between 1987 and 1999 by the
National Marrow Donor Program. Of these cases, 1175 (17%)
were HLA-DR matched but had an antigen level mismatch at
HLA-A or B. Mismatches within a CREG were deemed “minor”
using three published CREG matching schemes.
Univariate analyses (Kaplan-Meier for survival and cumulative
incidence for the other outcomes) suggest that outcome is not sig-
nificantly different between “minor” and “major” mismatches.
The table gives a comparison of outcomes with 95% conﬁdence
interval among the subset of HLA-DRB1 allele matched pairs
(N = 5181).
Multivariate analyses on all 6931 cases adjusting for diagnosis,
transplant center, HLA-DRB1 matching and other relevant risk
factors conﬁrmed these results. HLA-A,B matched cases had sig-
niﬁcantly better outcome than mismatched (“minor” or “major”)
cases, but there were no detectable differences between “major”
and “minor” mismatches. This provides a larger acceptable pool
of donors for patients without a perfect match.
PERIPHERAL STEM CELLS VERSUS BONE MARROW FROM UNRELATED
DONORS. A MATCH PAIR ANALYSIS OF 214 PATIENTS
Ringdén, O.1; Remberger, M.1; Blau, I.3; Ottinger, H.2; Kiehl, M.3;
Aschan, J.1; Beelen, D.2; Basara, N.3; Fauser, A.3; Runde, V.2 1. Hud-
dinge University Hospital, Stockholm, Sweden; 2. BMT Unit, Essen,
Germany; 3. BMT Unit, Idar-Oberstein, Germany
The clinical results between 107 patients receiving a G-CSF
mobilised peripheral blood stem cell graft (PBSC) graft from an
HLA-A, -B and -DR compatible unrelated donor were compared
to 107 matched controls receiving an unrelated bone marrow
(BM) transplant. Engraftment was achieved in 94% of the patients
in both the PBSC and the BM group. The PBSC graft contained
signiﬁcantly more nucleated cells, CD34+, CD3+ and CD56+ cells
(p<0.001) and resulted in a significantly shorter time to neu-
trophile (15 vs 19 days) and platelet engraftment (20 vs 27 days)
compared to the BM control group (p<0.001). Probability of acute
GVHD II-IV were 35% and 32% (ns), and probability of chronic
GVHD were 61% and 76% (ns), in the PBSC and BM groups,
respectively. There was no difference in bacteraemia, CMV reac-
tivation, CMV disease and fungal infection between the two
groups. Three years transplant related mortality (TRM) was 42%
in the PBSC group and 31% in the BM controls (ns) and survival
was 46% and 45%, respectively. Among patients with a malignant
disease, probability of relapse was 25% and 31% in the two
groups, respectively (ns), resulting in a disease-free survival of
43% in the PBSC group and 46% in the BM controls (ns). In
multivariate analysis early disease, acute GVHD 0-I and presence
of chronic GVHD were independent factors associated with a bet-
ter disease-free survival in this study.
Conclusion: PBSC from HLA-compatible unrelated donors
gives faster engraftment compared to bone marrow, but has other-
wise a similar outcome.
IMMUNITY OF PATIENTS SURVIVING 20-30 YEARS AFTER ALLOGENEIC
OR SYNGENEIC BONE MARROW TRANSPLANTATION
Storek, J.1; Espino, G.1; Douek, D.C.2; Dawson, M.A.1; Hill, B.2;
Mary, F.E.1; Martin, P.1; Maloney, D.G.1 1. Fred Hutchinson Cancer
Research Center, Seattle, WA; 2. University of Texas Southwestern
Medical Center, Dallas, TX
Background. The duration of immunodeﬁciency following mar-
row transplantation is not known.
Methods. Using questionnaires, we studied the infection rates
in 72 patients surviving 20-30 years after allogeneic or syngene-
ic marrow grafting. Furthermore, in 33 of the 72 patients and in
16 donors (siblings who originally donated the marrow) leuko-
cyte subsets were assessed by flow cytometry. T cell receptor
excision circles (TREC), markers of T cells generated de novo
(from hematolymphopoietic cells), were quantitated by real-
time PCR. IgG2 and antigen-specific IgG levels were deter-
mined by ELISA.
Results. Infections diagnosed after 15 years posttransplant
occurred rarely. The average rate was 0.07 infections per patient-
year or one infection every 14 years, excluding respiratory tract
infections, gastroenteritis, lip sores and hepatitis C. The counts of
monocytes, NK cells, B cells, total CD4 T cells and total CD8 T
cells in the patients were not lower than in the donors. The counts
of phenotypically naïve CD4 T cells and TREC+ CD4 T cells in
patients transplanted before the age of 18 years were similar to the
counts in their donors. These were approximately 50% lower in
patients transplanted at the age of ≥18 years compared to their
donors. The levels of total IgG2 and specific IgG against
Haemophilus inﬂuenzae and Streptococcus pneumoniae were sim-
ilar in patients and donors.
Conclusion. Overall, the immunity of patients surviving 20-30
years posttransplant is normal or near-normal. There appears to
be a minor, clinically insigniﬁcant deﬁciency of naïve CD4 T cells
in patients who were transplanted at age ≥18 but not in those who
were transplanted at age <18.
